The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy
Open accessAbstract
Purpose: The present report describes the development of paclitaxel-loaded gelatin nanoparticles for use in intravesical therapy of superficial bladder cancer. The commercial formulation of paclitaxel contains Cremophor, which forms micelles and thereby entraps the drug and reduces its partition across the urothelium. Experimental Design: Paclitaxel-loaded gelatin nanoparticles were prepared using the desolvation method, and their physicochemical and biological properties were characterized. Results: The size of the particles ranged from 600 to 1,000 nm and increased with the molecular weight of the gelatin polymer. Under optimal conditions, the yield was >80%, and the drug loading was 0.7%. Wide-angle X-ray diffraction analysis showed that the entrapped paclitaxel was present in an amorphous state, which has higher water solubility compared with the crystalline state. Identical, rapid drug release from nanoparticles was observed in PBS and urine, with ∼90% released at 37°C after 2 hours. Treatment with a protease (i.e., Pronase) rapidly degraded the nanoparticles, with half-lives of 23.8 minutes, 0.6 minute, and 0.4 minute in the presence of 0.01, 0.05, and 0.25 mg/mL Pronase, respectively. The paclitaxel-loaded nanoparticles were active against human RT4 bladder transitional cancer cells; the IC50 paclitaxel-equivalent concentrations were nearly identical to those of aqueous solutions of paclitaxel, i.e., ∼30 nmol/L (equivalent to ∼25 ng/mL) for 2-hour treatments and ∼4 nmol/L for 96-hour treatments. In dogs given an intravesical dose of paclitaxel-loaded particles, the drug concentrations in the urothelium and lamina propria tissue layers, where Ta and T1 tumors would be located, were 7.4 ± 4.3 μg/g (mean ± SD; 3 dogs; 9 tissue sections), which were 2.6× the concentrations we reported for dogs treated with the Cremophor formulation. Conclusions: Paclitaxel-loaded gelatin nanoparticles represent a rapid release, biologically active paclitaxel formulation that can be used for intravesical bladder cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 504
Dunne, M., Corrigan, O. I., & Ramtoola, Z. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00040-5 · Cited by 444
Taxol (paclitaxel): mechanisms of action.
Horwitz, S. B. (1994) · PubMed · Cited by 434
Schiff, P. B., & Horwitz, S. B. (1981) · Biochemistry · doi:10.1021/bi00514a041 · Cited by 368
Sparreboom, A., van Tellingen, O., Nooijen, W. J., & Beijnen, J. H. (1996) · PubMed · Cited by 313
Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial
Au, J. L.-S., Badalament, R. A., Wientjes, M. G., Young, D. C., Warner, J. A., Venema, P. L., Pollifrone, D. L., Harbrecht, J. D., Chin, J. L., Lerner, S. P., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.8.597 · Cited by 308
Self-citationHuizing, M. T., Keung, A. C., Rosing, H., van der Kuij, V, ten Bokkel Huinink, W. W., Mandjes, I. M., Dubbelman, A. C., Pinedo, H. M., & Beijnen, J. H. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2127 · Cited by 308
Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic Pathway
Woods, C. M., Zhu, J., McQueney, P. A., Bollag, D., & Lazarides, E. (1995) · Molecular Medicine · doi:10.1007/bf03401588 · Cited by 282
p53 and treatment of bladder cancer
Cote, R. J., Esrig, D., Groshen, S., Jones, P. A., & Skinner, D. G. (1997) · Nature · doi:10.1038/385123b0 · Cited by 269
Cited by
Biodegradable polymeric nanoparticles based drug delivery systems
Kumari, A., Yadav, S. K., & Yadav, S. C. (2010) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2009.09.001 · Cited by 3,724
Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles
Pinto Reis, C., Neufeld, R. J., Ribeiro, & Veiga, F. (2006) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.12.003 · Cited by 1,354
Basics and Recent Advances in Peptide and Protein Drug Delivery
Bruno, B. J., Miller, G. D., & Lim, C. S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.104 · Cited by 754
Gelatin-based nanoparticles as drug and gene delivery systems: Reviewing three decades of research
Elzoghby, A. O. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.019 · Cited by 651
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ma, P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000164 · Cited by 559
Metadata
- Authors
- Lu, Z., Yeh, T.-K., Tsai, M., Au, J. L.-S., & Wientjes, M. G.
- Venue
- Clinical Cancer Research
- Published
- 2004-11-15
- Volume
- 10
- Issue
- 22
- Pages
- 7677-7684
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2090075420
- Cited by
- 256
- References
- 31
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-1443
- The paper
- Lu, Z., Yeh, T.-K., Tsai, M., Au, J. L.-S., & Wientjes, M. G. (2004). Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-1443
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.